Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai Shyndec Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.15%.
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Shanghai Shyndec Pharmaceutical Co ROCE % Related Terms
Shanghai Shyndec Pharmaceutical Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) has a ROCE % of 6.15% as of Mar. 2026.
Is Shanghai Shyndec Pharmaceutical Co's ROCE % too high?
Shanghai Shyndec Pharmaceutical Co's current ROCE % is 6.15%. The Drug Manufacturers industry median ROCE % is 7.05. Shanghai Shyndec Pharmaceutical Co's value of 6.15% is 12.8% below this industry median. Overall, Shanghai Shyndec Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shyndec Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
Shanghai Shyndec Pharmaceutical Co's ROCE % of 6.15% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.05. Shanghai Shyndec Pharmaceutical Co's value of 6.15% is 12.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.05, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shyndec Pharmaceutical Co's current ROCE % of 6.15% is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shyndec Pharmaceutical Co's current ROCE % is 6.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shyndec Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co (SHSE:600420) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.08, compared to a current price of ¥8.47 — trading 23.6% below its estimated fair value. The current ROCE % is 6.15% and 12.8% below the Drug Manufacturers industry median of 7.05. Shanghai Shyndec Pharmaceutical Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shanghai Shyndec Pharmaceutical Co (SHSE:600420), the current ROCE % is 6.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.47 is trading 23.6% below its estimated GF Value™ of ¥11.08.
GuruFocus considers Shanghai Shyndec Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600420:
ROCE %: 6.15%
GF Value™: ¥11.08 vs. price of ¥8.47 (23.6% below fair value)
Industry Position: 12.8% below the Drug Manufacturers median
No single metric tells the full story. See the SHSE:600420 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shyndec Pharmaceutical Co Business Description
Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.
60GF Score
Get the complete analysis for SHSE:600420
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600420 has been successfully added to your 
